surgery for cervical myelopathy
Conditions
Interventions
Product Name: NA
Product Code: NA
Pharmaceutical Form: Emulsion for infusion
INN or Proposed INN: Propofol
Concentration unit: mg/ml milligram(s)/millilitre
Concentration number: 10-
Product Name: Se
Sponsors
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with acute symptoms or signs of cervical myelopathy undergoing cervical spine surgery, aged 18 to 75 years, classified as American Society of Anesthesiology physical status (ASA) I-III, were enrolled Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients with preoperative hemodynamic instability and pulmonary failure were excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: This trial was designed to evaluate the hemodynamic and ventilator effects of propofol-based or sevoflurane-based anesthesia induction, in patients undergoing surgery for cervical myelopathy;Secondary Objective: Secondary end-points included the relationship between the two anesthesia induction strategies and intubation conditions as assessed by the Copenhagen score rearranged for fiberoptic intubation, according to jaw relaxation, resistance to fiberoptic bronchoscopy, vocal cord position and movements and reaction to cuff inflation;Primary end point(s): The MAP was measured at 4 time points: before anesthesia induction (T1: baseline), at the end of anesthesia induction when an adequate sedation level, with BIS values 40-50, was achieved (T2: sedation steady state); immediately after placement of the endotracheal tube (T3: intubation); five minutes after tracheal intubation (T4: post-intubation). | — |
Countries
Italy
Outcome results
None listed